Treatment Compliance Clinical Trial
Official title:
IN VIVO AND IN VITRO COMPARATIVE STUDY ON EFFICACY OF ANSA (Experimental Drug) & CRAN MAX (Control Drug) SACHET IN UNCOMPLICATED UTI
I This clinical trial aims to VIVO AND IN VITRO COMPARATIVE STUDY ON EFFICACY OF ANSA (experimental drug) & CRAN MAX (control drug) SACHET IN UNCOMPLICATED UTI in females. The main question[s] it aims to answer are: • Hypothesis I ANSA is an effective therapy for uncomplicated UTI treatment and inhibits or kills E.coli and other organisms in vitro and in vivo Null Hypothesis ANSA is not an effective therapy for uncomplicated UTI treatment and couldn't inhibit or kill E.coli and other organisms in vitro and in vivo Hypothesis II Cran Max is an effective therapy for uncomplicated UTIs and inhibits or kills E.coli and other organisms in vitro and in vivo Null Hypothesis Cran Max is not an effective therapy for uncomplicated UTI treatment and couldn't inhibit or kill E.coli and other organisms in vitro and in vivo
In this study, the emphasis is to evaluate the in vivo & in vitro efficacy of Ansa sachet having three APIs (Vaccinium macrocarpon, Saraca indica, Cimicifuga racemosa) in comparison with Cran max sachet in female patients having uncomplicated UTI. It is a single-blinded, randomized controlled trial. UTI (urinary tract infection) is mainly caused by E.coli and other associated organisms about 80% in females of fertile age and it occurs with less percentage in males. Uncommon recurrent UTIs is more prevalent in females than males. Post-menopausal women have higher rates of UTIs because of pelvic prolapse, lack of estrogen, loss of lactobacilli in the vaginal flora, increased peri-urethral colonization by Escherichia coli (E. coli), and a higher incidence of medical illnesses such as diabetes mellitus (DM).The microorganism that causes UTIs is similar, in most cases, to the sporadic infection. Most uro-pathogens from the rectal flora ascend to the bladder after colonizing in the peri urethral area and urethra. Keeping in mind that Helix Pharma designed ANSA in such a combination that it not only helps in the prevention of UTIs but also decreased recurrent UTIs as other APIs in ANSA have the capacity to normalize hormonal levels in females which is the basic cause of peri-menopausal and menopausal woman. The objective is to do a comparison of whether the Ansa sachet (experimental drug) or cran max sachet (control group) is a clinically good choice. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02209220 -
Impact of Automatic Positive Airway Pressure on Treatment Compliance in OSA Patients Awaiting Bariatric Surgery
|
N/A | |
Enrolling by invitation |
NCT06070415 -
Adherence to Exercises for Low Back Pain.
|
N/A | |
Completed |
NCT04393987 -
Effect Of Treatment Compliance Training Given To Patients With Bipolar Disorder
|
N/A | |
Completed |
NCT04809519 -
Integrative Nursing Based Multimodal Interventions for Uncontrolled Hypertensives
|
N/A | |
Not yet recruiting |
NCT05941923 -
Respiratory Critical Care Nurse Training Program
|
N/A | |
Completed |
NCT04853836 -
Olfactory Disfunction and Co-ultraPEALut
|
Phase 4 | |
Completed |
NCT06325579 -
Immersive Virtual Reality for Dysphagia
|
N/A | |
Not yet recruiting |
NCT06421038 -
Efficacy of Thyme Honey in The Management of Oral Aphthous Ulcers
|
N/A | |
Completed |
NCT04370145 -
Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy
|
Phase 4 | |
Active, not recruiting |
NCT04536844 -
Telehealth Follow-up in Patients With Rheumatoid Arthritis
|
N/A | |
Recruiting |
NCT05844579 -
The ICU LIBERATION Study
|
||
Recruiting |
NCT05465408 -
Culturally Aware AET Non-Initiation Intervention
|
N/A | |
Active, not recruiting |
NCT05115994 -
Antihypertensive and PAP Treatment in Obstructive Sleep Apnea Patients With Hypertension (AHPAP)
|
||
Not yet recruiting |
NCT04517032 -
ColoRectal Cancer in India: catastrOphiC expenDIture and Referral Pathways infLuencE on Presentation and Treatment
|